Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552183 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
A Phase 1 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05552183: Completed Phase 1 study, sponsored by CTI BioPharma.
NCT05552183 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05552183, a Phase 1 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a Phase 1 study designed to assess the effect of hepatic insufficiency on the PK of pacritinib by study of 14-day BID dosing of pacritinib in subjects with moderate and severe hepatic impairment compared to healthy matched control subjects with normal liver function. Safety and tolerability of multiple day dosing of pacritinib in the subject populations will also be evaluated.
Primary Outcome
To characterize and compare the steady-state PK profile of multiple doses (14 days) of 200 mg BID pacritinib in subjects with moderate and severe hepatic impairment with that of healthy matched control subjects with normal liver function.
Interventions
- DRUG oral dose of 200 mg pacritinib twice daily (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2024-06-10 |
| Phase | Phase 1 |
What the finished NCT05552183 record still lists
NCT05552183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 1 intervention - of which oral dose of 200 mg pacritinib twice daily (BID) is the first listed.
NCT05552183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05552183 about?
NCT05552183 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and PK of Pacritinib". This is a Phase 1 study designed to assess the effect of hepatic insufficiency on the PK of pacritinib by study of 14-day BID dosing of pacritinib in subjects with moderate and severe hepatic impairment compared to healthy matched control subjects with normal liver function. Safety and tolerability ...
What is the current status of trial NCT05552183?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2022-12-12. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT05552183?
The interventions under investigation include: oral dose of 200 mg pacritinib twice daily (BID) (DRUG).
Who is sponsoring clinical trial NCT05552183?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05552183's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI